29 February 2016
Merck Animal Health Awards Scholarships to Swine Veterinary Students
Madison, N.J., February 29, 2016 – In partnership with the American Association of Swine Veterinarians Foundation (AASVF) – the charitable arm of the American Association of Swine Veterinarians – Merck Animal Health today announced the 2016 recipients of the AASVF/Merck Animal Health Veterinary Student Scholarships.
“Merck Animal Health is committed to supporting the education of the next generation of swine industry leaders,” said Jamie Lehman, D.V.M., Associate Director of Swine Technical Services, Merck Animal Health. “We remain dedicated to providing veterinary students with vital real-world experiences that will equip them with the skills they need to help ensure the health and well-being of animals, as well as help feed the world.”
“It is gratifying to see Merck Animal Health recognize the value and significance of supporting veterinary students pursuing a career in swine medicine and production,” said Tom Burkgren, D.V.M., AASV Executive Director. “The AASVF greatly appreciates the company’s commitment to supporting the mission of the development of students and veterinarians, as they will play an integral role in the future of our industry.”
The recipients, who will each receive a $5,000 scholarship, are:
- Alyssa Anderson, University of Minnesota
- Daniel Carreno, North Carolina State University
- Emily Mahan-Riggs, North Carolina State University
- Rachel Schulte, Iowa State University
- Thomas Wurtz, Washington State University
The recipients were announced earlier today at the 47th Annual AASV Meeting in New Orleans, La. Second- and third-year veterinary students enrolled in American Veterinary Medical Association-accredited or recognized colleges of veterinary medicine in the United States, Canada, Mexico, South America and the Caribbean Islands are eligible. Learn more at www.aasv.org
About Merck Animal Health
Today's Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn and Twitter.
About the AASVF
The American Association of Swine Veterinarians (AASV) has approximately 1,300 members involved in practice, industry and academia in more than 40 countries. It is the mission of the AASV to: increase the knowledge of swine veterinarians, protect and promote the health and well-being of pigs, advocate science-based approaches to veterinary, industry, and public health issues, promote the development and availability of resources that enhance the effectiveness of professional activities, create opportunities that inspire personal and professional growth and interaction and mentor students, encouraging life-long careers as swine veterinarians. The AASV Foundation (AASVF) is the charitable arm of the AASV. One of the AASVF’s objectives is to provide oversight and manage veterinary student scholarship programs. For more information, visit www.aasv.org.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).